Uroquant
Private Company
Funding information not available
Overview
Uroquant is a private, pre-revenue diagnostics company focused on transforming bladder cancer detection. Its core technology is a mass spectrometry-based assay that detects specific protein biomarkers from a simple urine sample, offering high sensitivity and a non-invasive patient experience. The company is positioned to address significant unmet needs in urological diagnostics, particularly for monitoring and initial detection, though it faces competition and the challenge of achieving clinical adoption and reimbursement. Uroquant's success hinges on validating its test, securing regulatory approvals, and successfully commercializing its product.
Technology Platform
Mass spectrometry-based proteomic assay for detecting cancer-specific protein biomarkers in urine.
Opportunities
Risk Factors
Competitive Landscape
The non-invasive bladder cancer diagnostic space is competitive, with companies like Pacific Edge (Cxbladder, mRNA), Nucleix (Bladder EpiCheck, methylation), and others developing urine-based assays. Uroquant differentiates with its mass spectrometry proteomics approach, but faces competitors with commercial head starts and alternative technologies.